Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion launches phase III trials of new antibiotic

Actelion launches phase III trials of new antibiotic

11th September 2013

Actelion has announced that it will be initiating a phase III clinical development programme for its novel antibiotic therapy cadazolid.

The drug will be assessed as a means of treating patients with Clostridium difficile-associated diarrhoea, with two identical multicentre, randomised, double-blind studies to compare its effectiveness to that of vancomycin.

Its aim is to determine whether the clinical response after administration of cadazolid is non-inferior to vancomycin and whether it can offer any benefits, with more than 1,250 patients to be enrolled in the studies.

Actelion expects to commence recruitment for the trials in the fourth quarter of 2013.

Dr Jean-Paul Clozel, chief executive officer of Actelion, said: "The promising profile of cadazolid underlines Actelion's commitment to finding new classes of antibiotics which have a reduced risk of developing resistance."

Last month, the firm highlighted data from a new study published in the New England Journal of Medicine that demonstrated the efficacy of the pulmonary arterial hypertension therapy Opsumit.ADNFCR-8000103-ID-801636085-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.